Synergic Antitumor and Antitoxicity Effects of the Traditional Uyghur Medicine Abnormal Savda Munziq when Combined with 5-Fluorouracil

Ainiwaer Aikemu
(First author)
Central Laboratory
Xinjiang Medical University
Urumqi, Xinjiang, China
e-mail: ainiwa@sina.com

YingYing Liu
Department of Oncology
Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University
Urumqi, Xinjiang, China
e-mail: 987356231@qq.com

Zhen Gao
National Clinical Research Base of Traditional Chinese Medicine of Xinjiang
Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University
Urumqi, Xinjiang, China
e-mail: gaozhening@gmail.com

Lianlian Shan
Department of Drug Analysis
Xinjiang Medical University
Urumqi, Xinjiang, China
e-mail: happyshanlian@sina.com

Aerziguli Tuerxun
Clinical Medical Research Institute
The First Affiliated Hospital of Xinjiang Medical University
Urumqi, Xinjiang, China
e-mail: 396737815@qq.com

Halmurat Upur*
(Corresponding author)
Traditional Uighur Medicine and Pharmacology
Xinjiang Medical University
Urumqi, Xinjiang, China
e-mail: halmurat@263.net

Abstract—Objective: A number of traditional Uyghur medicines have been recognized as potent antitumor agents and have been developed and analyzed in vivo. In the present study, the toxic, therapeutic and cytotoxic properties of the Uyghur medicine Abnormal Savda Munziq (ASMq) were investigated. In the presence of certain agents, ASMq results in the fragmentation of plasmid DNA, indicating that it may be a potent antitumor agent in vivo, as it appears to bind to DNA molecules. Thus, the present study investigated the effects of ASMq in combination with 5-fluorouracil (5-FU) in vivo, using an S180 mouse model of cancer. ASMq was observed to enhance the antitumor effect of 5-FU and also attenuated the cytotoxicity of the oxidative stress reactions. Methods: The mice were divided randomly into six groups. Influence of treatment on the activity of mice were observed. The serum levels of SOD, MDA, GSH-Px and pathological change were determined. Results: Compared with the model group, the data turned normal after gavaged 5-FU and ASMq. Conclusion: In summary, a combination of ASMq and 5-FU resulted in a synergistic antitumor effect and attenuated toxicity, suggesting that ASMq may be clinically applicable for the treatment of certain types of cancer.

Keywords-Traditional Uyghur Medicine; Abnormal Savda Munziq; 5-Fluorouracil; Antitumor Effects; Antitoxicity Effects
pyrimidines uracil and thymidine. 5-FU contains a fluorine atom substituted in the carbon-5 position and modulates the enzyme thymidylate synthetase, which in turn blocks the synthesis of DNA. 5-FU has been employed successfully in the treatment of gastrointestinal malignancies, carcinoma of the aero-digestive tract, breast cancer and bladder cancer [7,8]. In the present study, the effects of ASMq combined with 5-FU were investigated in vivo using an S180 cancer mouse model. It was hypothesized that ASMq may enhance the antitumor effects of 5-FU, and attenuate the associated levels of oxidative stress.

II. MATERIALS AND METHODS

A. Ethical approval of the study protocol

The present study protocol was approved by the Ethics Committee of Xinjiang Medical University (Urumqi, China).

B. Reagents

ASMq was obtained as a granular formulation from Xinjiang Qikang Habo Uyghur Medicine Co., Ltd. (Urumqi, China; Batch Number: 06060). 5-FU was obtained from Tianjin Jinyao Amino Acid Co., Ltd. (Tianjin, China; Batch Number: 0912302). The physiological saline was obtained from Sinopharm Xinjiang Pharmaceutical Co., Ltd. (Batch number: 11030831). The Superoxide dismutase (SOD) kit was purchased from the Nanjing Jiancheng Bioengineering Institute (Nanjing, China; Batch Number: 20100420). The malondialdehyde (MDA) kit was purchased from the Nanjing Jiancheng Bioengineering Institute (Nanjing, China; Batch Number: 2100420). The glutathione peroxidase (GSH-Px) kit was purchased from the Nanjing Jiancheng Bioengineering Institute (Nanjing, China; Batch Number: 20100420).

C. Animals

In total, 60 healthy Kunming mice (weight, 20±2 g; age, 4-6 weeks; gender, 30 males and 30 females) were obtained from Xinjiang Medical University Experimental Animal Center (license no. 2003-001; Urumqi, China).

D. Preparation of the S180 mouse model

Kunming mice were bred under standard laboratory conditions at room temperature, with a 12h light dark cycle and free access to standard rodent chow and water. The mice were divided randomly into six groups: control group, model group, 5-FU group, high-dose ASMq+5-FU group (ASMq.H), medium-dose ASMq+5-FU group (ASMq.M), low-dose ASMq+5-FU group (ASMq.L), 10 mice per group, each group half male and half female. A total of 60 mice in the control group except for the remaining five groups (50 mice) were inoculated with s180 cells.

E. Method

S180 cells were supplied by Laboratory Animal Centre of Xinjiang military hospital. Cream colored ascites were extracted from the Kunming mouse which was Inoculated seven days old mice under aseptic conditions. Using high pressure antiseptic physiological saline Diluted to the ascites 1x10^7 cells/ml. With the exception of the control group, 0.2 ml ascites (1x10^7 cells/ml) were transplanted into the right axilla of all the mouse, the entire operation is completed under sterile conditions within 30 minutes. After 24 h, the intervention was continued according to the body weight of the mouse.

The control and model groups were daily injected with (0.2 ml/10 g body weight) physiological saline (NS) via the intraperitoneal (i.p.) route and NS (0.2 ml/10 g body weight) via the intragastric (i.g.) route. The positive control (5-FU) group received 5-FU (i.p, 25 mg/kg) on day 1, 3, 5, 7, and 9 (a total of five doses). The ASMq.H group received 5-FU (i.p., on day 1, 3, 5, 7 and 9, 25 mg/kg) + high-dose ASMq (i.g, 8 g/kg daily); the ASMq.M group received 5-FU (i.p., on day 1, 3, 5, 7 and 9, for25 mg/kg) + medium-dose ASMq (i.g, 4 g/kg daily); and the ASMq.L group received 5-FU (i.p., on day 1, 3, 5, 7 and 9, 25 mg/kg) + low-dose ASMq (i.g, 2 g/kg daily). The mice were euthanized ten days after the start of the experiment. The thymus, spleen, liver and tumors were removed and weighed respectively.

F. Determination of serum levels of SOD, MDA and GSH-Px

Following the establishment of the S180 mouse model and continual dosing with ASMq for ten days, blood samples were collected via the eye socket. The samples were centrifuged at 3,000 rpm for 20 min at room temperature (25℃) in order to obtain the sera. The serum levels of SOD, MDA, GSH-Px were determined by xanthine oxidase method, thiobarbituric acid (TBA) method and Ellman method according to the kit manufacturer’s instructions strictly.

G. Statistical analysis

Data are expressed as the mean ± SD. SPSS software, version 17.0 (SPSS, Inc., Chicago, IL, USA) was used for analyses. P<0.05 was considered to indicate a statistically significant difference.

III. RESULTS

A. Influence of treatment on the activity of mice

Following treatment, animals’ behavior, autonomic activities, food intake, water intake, fur quality, feces and urine have been observed by the naked eye comparison as normal mice behavior. The model group exhibited reduced activity, enlarged tumors, unclean fur and listlessness, with a tumor growth incubation period (TT) of two days and the fastest tumor growth velocity (TS) of the groups. The ASMq.L group exhibited normal activity, good
mental state and clean fur, with a TT of three days and increased TS compared with the model group. The ASMq.M group exhibited normal activity, with an improved mental state and fur cleaning behavior compared with the ASMq.L group. Furthermore, the TT was three days and the TS was reduced compared with the ASMq.L group. The ASMq.H group also displayed normal activity, with a mental state and fur cleaning behavior that was increased compared with the ASMq.L and ASMq.M groups. The ASMq.H TT was three days and the TS was reduced compared with the ASMq.L and ASMq.M groups. In the 5-FU group, normal activity and a good mental state and clean fur were observed, which were improved compared with the ASMq.L group. The TT was four days and the TS was the lowest of the groups.

B. Influence of treatment on weight of internal organs/body weight

Subsequent to the processing of tissue samples from the thymus, spleen and liver, the mass ratio of these internal organs was calculated using the following formula: Mass ratio = organ weight (g)/body weight (g).

Compared with the model, in the ASMq.H, ASMq.M, ASMq.L and the 5-FU groups, tumors were reduced in size, indicating that the normal functions of the tumors were weakened. The thymus weight in the ASMq.H, ASMq.M and ASMq.L groups were increased compared with the model group (P<0.05). Compared with the model and 5-FU group, in the ASMq.M group the spleen weight was increased (P<0.05), in the ASMq.L groups the liver weight were increased (P<0.05). (Table I.)

The tumor inhibition rate values in the 5-FU, ASMq.H, ASMq.M and ASMq.L groups were 48.02, 52.26, 66.41 and 44.87%, respectively, indicating that tumor function had been inhibited by these treatments. An evident increase was observed in the thymus/body weight ratio of the ASMq.H and ASMq.L groups compared with the model group (P<0.05). A statistically significant increase was observed in the spleen/body weight ratio of the ASMq.H, ASMq.M and ASMq.L groups compared with the 5-FU group (P<0.05). Compared with the model group and the 5-FU group, the liver/body weight ratio of the ASMq.H group was decreased, in the ASMq.L group was increased (P<0.05). (Table II.)

| Table I. Antitumor Activity of ASMq in an S180 Tumor Mouse Model (x±SD) |
|---|---|---|---|---|
| Group | Tumor (g) | Thymus (g) | Spleen (g) | Liver (g) | Weight (g) |
| Control | 0.00±0.00 | 0.10±0.02 | 0.10±0.01 | 1.20±0.05 | 29.64±0.84 |
| Model | 0.57±0.03 | 0.09±0.03 | 0.11±0.01 | 1.20±0.05 | 30.65±2.61 |
| 5-Fu | 0.29±0.02 | 0.06±0.01 | 0.08±0.01 | 1.14±0.04 | 25.24±0.54 |
| ASMq.H | 0.26±0.03*△ | 0.11±0.01* △ | 0.11±0.01* △ | 1.16±0.10 | 31.25±0.65*△ |
| ASMq.M | 0.19±0.02*△ | 0.09±0.01* △ | 0.12±0.02* △ | 1.33±0.36 | 30.39±1.30*△ |
| ASMq.L | 0.31±0.01*△ | 0.10±0.02* △ | 0.11±0.02* △ | 1.35±0.18* △ | 26.55±0.67*△ |

Note: *P<0.05, compares with the model group; △ P<0.05, compares with the 5-Fu group

| Table II. Inhibitory Effect of ASMq on the Growth of Transplanted Tumors in S180 Mice and Organ/Weight Ratio |
|---|---|---|---|---|
| Group | Thymus/body weight (g/g) | Spleen/body weight (g/g) | Liver/body weight (g/g) | Inhibitory rate (%) |
| Control | 0.0035±0.0007 | 0.0034±0.0005 | 0.0404±0.0018 | 48.02 |
| Model | 0.0029±0.0010 | 0.0037±0.0007 | 0.0415±0.0041 | 44.78 |
| 5-Fu | 0.0024±0.0003 | 0.0030±0.0004 | 0.0452±0.0017 | 44.78 |
| ASMq.H | 0.0034±0.0004*△ | 0.0034±0.0004*△ | 0.0370±0.0037*△ | 52.26 |
| ASMq.M | 0.0029±0.0004*△ | 0.0039±0.0006*△ | 0.0434±0.0112 | 66.41 |
| ASMq.L | 0.0039±0.0005*△ | 0.0040±0.0006*△ | 0.0506±0.0066*△ | 44.78 |

Note: *P<0.05, compares with the model group; △ P<0.05, compares with the 5-Fu group
C. Effect of ASMq treatment on serum levels of SOD, MDA and GSH-Px

The ASMq.M group exhibited the highest levels of SOD and GSH-Px compared with the model group and hard upon to the control group value (P<0.05). Furthermore, the 5-FU group exhibited significantly lower levels of SOD and GSH-Px comparing with the model group (P<0.05). The ASMq.M and ASMq.H groups exhibited significantly increased levels of SOD and GSH-Px compared with the 5-FU group (P<0.05). (Fig.1)

The ASMq.M group displayed significantly lower MDA levels comparing with the model group (P<0.05). The ASMq groups exhibited significantly reduced levels of MDA comparing with the 5-FU group (P<0.05). (Fig.2)

D. Tumor pathology

As can be observed in Fig.3, the 5-FU group sections presented clear tumor tissue damage compared with the model group, including large areas of tissue necrosis that was primarily eosinophilic. There were small areas of tissue necrosis in the ASMq.L group, while large areas of tissue necrosis were observable in the ASMq.M and ASMq.H groups. The ASMq.M group exhibited evident ischemic necrosis and phlogocyte infiltration. (Fig.3)

IV. DISCUSSION

A previous study indicated that ASMq possesses antitumor and immunomodulatory properties [9]. In the present study, ASMq was observed to significantly inhibit the growth of transplanted mouse tumors compared with model mice, and it increased relative spleen weights compared with those receiving 5-FU treatment alone, suggesting that ASMq exerted an antitumor effect and stimulated splenocyte proliferation.

However, in contrast to the notable antitumor and immunomodulatory activities of ASMq in mice, ASMq previously displayed a weak cytotoxic effect on tumor cells in vitro [10]. This contradiction suggests that ASMq may exert an antitumor effect by enhancing immune function rather than by directly attacking cancer cells, in a similar manner to the polysaccharides from mushrooms [11]. Thus, ASMq may possess considerable potential for development as an adjuvant of chemotherapy drugs due to its immunomodulatory activity and low toxicity.

5-FU is one of the most effective chemotherapeutic agents available for treating numerous types of solid tumors [12]. However, the continuous use of 5-FU is not
always feasible due to cumulative toxicity. Therefore, it is essential to develop new adjuvant therapies that protect patients with cancer from the harmful side effects of chemotherapy, without reducing the efficacy of the treatment. In the present study, the antitumor effect of ASMq in combination with 5-FU was evaluated in a mouse model of S180 cancer. The results indicated that ASMq exerted a significant synergistic antitumor effect in combination with 5-FU. Furthermore, the 5-FU-induced reduction in the relative weight of the thymus and spleen was reversed by the ASMq treatment. These results further demonstrated the association between the antitumor effect of ASMq and its immunomodulatory activity and confirmed its potential for development as an adjuvant to chemotherapy drugs.

Lipid peroxidation is an important mechanism with respect to cell damage. According to free radical theory, the more rapid the metabolic rate of an organism, the higher the production of free radicals and the shorter the lifespan [13,14]. Furthermore, the activity of antioxidant enzymes, particularly SOD, has been reported to slow the aging process [15]. It has been reported that SOD slows aging and inhibits oxidative damage [16], and this may be due to irreversible inactivation by its product, hydrogen peroxide. An alternative explanation for this reduction may be the increase in the glycation of SOD [17]; and it was demonstrated in the present study that 5-FU may reduce the activity of SOD and GSH-Px and increase levels of MDA. MDA is the final product of lipid peroxidation of the cell membrane; therefore, MDA levels may reflect the intensity of lipid peroxidation. SOD and GSH-Px are used to evaluate resistance to oxidative damage [18,19]. Studies have suggested that a combined therapy of 5-FU with ASMq may be a clinically applicable adjuvant treatment in combination with cancer chemotherapy [20,21].

In conclusion, ASMq was observed to enhance the antitumor effect of 5-FU and to attenuate the cytotoxicity of associated oxidative stress reactions. A synergistic antitumor effect and attenuated toxicity were obtained using a combined treatment of ASMq with 5-FU. Thus, ASMq may be potentially useful in the clinical treatment of cancer, and future studies should assess the synergistic and attenuated action of ASMq clinically in the treatment of fibrosarcoma(S180).

ACKNOWLEDGMENT

The present study was supported by grants from the Ministry of Education Changjiang Scholar and Innovative Team Development Program of China (no. IRT0977) and the National Natural Science Foundation of China (no. 30260128 and 81360668).

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

REFERENCES
